2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2487

Clinical Practices Participating in a Quality Improvement Project Make Progress in Implementing Population Management

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2860

Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2687

Clinical Significance of Patient-Reported Pain and Stiffness at Each Joint Level in the Evaluation of Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2619

Clinical Usefulness of Periodic Detection of Serum 14-3-3Î· for Predicting Efficacy of Tocilizumab in RA

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2758

Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2304

Clinical, Ultrasonographic and Neurophysiological Correlation of Patients with Carpal Tunnel Syndrome in Santo Domingo, Dominican Republic

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2655

Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2802

Co-Occurence of Anti-Ro52/TRIM21 and Anti-TRIM38 Autoantibodies Is Associated with Higher Severity of Dry Eye in Sjögren’s Syndrome

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 3049

Cognitive Dysfunction in Chronic Progressive Neuro-Behçet’s Disease: Comparative Study of the Brainstem and Hippocampus Region Using Brain Magnetic Resonance Imaging

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2955

Cognitive Impairment in Lupus Patients: Identification of the Best Screening Test and Assessment for Associated Factors

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 3007

Cold Receptor Expression and Function in Human Dermal Fibroblast: Possible Role in the Pathogenesis of Scleroderma Fibrosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2917

Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2557

Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2570

Comparative Analysis of Collagen-Antibody Induced Arthritis and the Arthritis Inhibitory Potential of Specific ACPA in Two Mouse Subspecies Genetically Separated about One Million Years Ago

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2767

Comparative Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated By Serum Amyloid a

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].